All FDA articles
-
BusinessUS approves schizophrenia drug with new mode of action
Cobenfy promises to better address negative symptoms than existing antipsychotics
-
BusinessMDMA rejection poses questions for psychedelic drug trials
Decision prompts reflection over how psychotherapy is involved, regulating combination treatments and safeguarding patients
-
OpinionThe US abortion drugs regulation challenge has stalled, but it will return
Having failed in the US Supreme Court, anti-abortion activists are trying other ways to prevent access to mifepristone
-
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessLife-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
-
BusinessUS regulator says phenylephrine is ineffective as a decongestant
FDA will begin consultation on removing the drug from hundreds of over-the-counter remedies
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
OpinionWill a court overturn abortion drug’s approval?
Tangle between regulation and politics makes uncomfortable viewing from industry
-
-
NewsLab-grown chicken nears the dinner table in the US
Upside Foods’ chicken filet product is the first cell-grown meat product to be declared safe for consumption by the FDA
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
NewsRush to approve Covid vaccine prompted by politics may end in disaster
Push by governments to pass a vaccine without appropriate evidence could damage fight against virus
-
OpinionHopes and fears for remdesivir
Available resources for testing coronavirus treatments need to be used wisely
-
NewsSurvey of US government scientists reveals politicisation worries under Trump
Political appointees and business influence blamed for damaging agencies’ ability to make science-based decisions
-
BusinessCan existing drugs slow Covid-19?
The fastest route to treatments may be to repurpose existing drugs – if they work
-
BusinessFDA freezes foreign facility inspections amid coronavirus pandemic
US regulator will rely on border checks and shared data, but some approval processes may be delayed
-
BusinessCoronavirus pandemic will disrupt international supply chains
Halted production and transport restrictions are straining industries that rely heavily on China for supplies